<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02453867</url>
  </required_header>
  <id_info>
    <org_study_id>REDUCE</org_study_id>
    <secondary_id>2014-002643-18</secondary_id>
    <nct_id>NCT02453867</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a Reduced Immunosuppression vs. Standard Triple Therapy in Senior Renal Transplant Recipients</brief_title>
  <acronym>REDUCE</acronym>
  <official_title>Multicenter, Prospective, Randomized Study Investigating the Efficacy and Safety of a Reduced Immunosuppressive Therapy With Tacrolimus Once Daily in Comparison to Standard Triple Immunosuppression in Senior Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klemens Budde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Renal Association - European Dialysis and Transplant Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Kidney Transplant Association (EKITA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DESCARTES Working Group On Transplantation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study purpose To establish efficacy and safety of a reduced immunosuppressive therapy with&#xD;
      tacrolimus once daily for senior (&gt;65 years of age) renal transplant recipients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study outline Stable senior transplant recipients (&gt;65 years of age) participating in the&#xD;
      European SENIOR transplant registry may enter the trial at month 3 post-transplant, if they&#xD;
      fulfil all of the in- and none of the exclusion criteria. At this time patients will be&#xD;
      randomized 1:1 either to continue&#xD;
&#xD;
      Reference therapy:&#xD;
&#xD;
      Tacrolimus once daily (Advagraf®) Mycophenolate (either MMF ≥1g/d or EC-MPS ≥720g/d) Steroids&#xD;
      (≥5mg prednisolone or equivalent) or to Investigational therapy: Tacrolimus once daily&#xD;
      (Advagraf®) Steroid stop at month 3 (tapering within 2 weeks) Mycophenolate stop at month 6&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">December 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined efficacy endpoint (BPAR, graft loss and death)</measure>
    <time_frame>between randomization and month 12 posttransplant (month 9 of the study)</time_frame>
    <description>BPAR (biopsy proven acute rejection)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of severe infections</measure>
    <time_frame>between randomization and month 12 posttransplant</time_frame>
    <description>Numbers, type of infections will be registered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of opportunistic infections</measure>
    <time_frame>between randomization and month 12 posttransplant</time_frame>
    <description>CMV infections, BKV infections; numbers, type of infection will be registered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalisations and days of hospitalisation</measure>
    <time_frame>between randomization and month 12 posttransplant</time_frame>
    <description>number of episodes, days in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function by calculated glomarular filtration rate calculated by CKD-EPI</measure>
    <time_frame>between randomization and month 12 posttransplant</time_frame>
    <description>Comparison of estimated glomerular filtration rate calculated by CKD-EPI formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of occurrences and types of donor specific antibodies (DSA)</measure>
    <time_frame>between randomization and month 12 posttransplant</time_frame>
    <description>surveillance of detection of new donor specific antibodies by Luminex assay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Immunosuppression After Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>Standard immunosuppression</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>starting immunosuppression: tacrolimus (Advagraf) (target trough levels &gt;5 ng/ml), mycophenolate mofetil &gt;1g/d in MMF or &gt;720 mg/d in mycophenolic acid, steroids from month 1-3 dosing according to local practice; 200 pts are planned to carry on with standard immunosuppression (tacrolimus (Advagraf), Mycophenolate, steroids) as stated above according to international guidelines for kidney transplant recipients from month 3 posttransplant to month 12 posttransplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced immunosuppression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Intervention is stopping medication:&#xD;
200 pts are planned to receive a reduced immunosuppression after month 3: carry on with tacrolimus (Advagraf; trough levels &gt;5 ng/ml) steroids stop at month 3 mycophenolate stop at month 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reduced immunosuppression</intervention_name>
    <description>Stop steroids at month 3 Stop mycophenolate at month 6 continue tacrolimus once daily (Advagraf, trough levels &gt; 5ng/ml) Stop mycophenolate at month 6</description>
    <arm_group_label>Reduced immunosuppression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus is used in both the acitve comparator arm and the interventional arm</description>
    <arm_group_label>Reduced immunosuppression</arm_group_label>
    <arm_group_label>Standard immunosuppression</arm_group_label>
    <other_name>Advagraf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate</intervention_name>
    <description>Mycophenolate is used in the acitve comparator arm for the whole study period; Mycophenolate is stopped at month 6 after Transplantation (month 3 of the study) in the experimental arm</description>
    <arm_group_label>Reduced immunosuppression</arm_group_label>
    <arm_group_label>Standard immunosuppression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroids</intervention_name>
    <description>Steroids are used continually in the active comparator arm and are stopped at the beginning of the study (month 3 after Transplantation) as an Intervention in the experimental arm</description>
    <arm_group_label>Standard immunosuppression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females, aged ≥65 years and participating in the European SENIOR transplant&#xD;
             registry&#xD;
&#xD;
          2. Patients who received a renal allograft 3 - 3.5 months prior to randomization.&#xD;
&#xD;
          3. Patient must have received primary or secondary renal allograft from a blood group&#xD;
             compatible donor&#xD;
&#xD;
          4. Standard criteria donors (SCD), expanded criteria donors (ECD), donors after cardiac&#xD;
             death (DCD) and living donors (LD) are eligible&#xD;
&#xD;
          5. Patients who are willing and able to participate in the study and from whom written&#xD;
             informed consent has been obtained&#xD;
&#xD;
          6. Patients on continuous standard triple therapy with tacrolimus once daily (Advagraf,&#xD;
             trough level ≥5ng/ml) in combination with mycophenolate (either ≥1.0g/day MMF or&#xD;
             ≥720mg/d EC-MPS) and steroids (≥5mg prednisolone or equivalent) since transplantation&#xD;
&#xD;
          7. Stable graft function with serum creatinine ≤2.5 mg/dl.&#xD;
&#xD;
          8. Patients with low to standard immunological risk, who had a PRA over 20% and no known&#xD;
             donor specific antibodies (DSA) at transplantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with mental dysfunction or inability to comply with the study protocol&#xD;
&#xD;
          2. Patients, who - according to the investigator - require for medical reasons (e.g.&#xD;
             previous rejections) continuous triple therapy or a different tacrolimus exposure&#xD;
&#xD;
          3. Multi-organ recipients (other solid organ (e.g. pancreas) or bone marrow)&#xD;
&#xD;
          4. Blood group ABO-incompatible allografts&#xD;
&#xD;
          5. Patients who suffered from severe T-cell mediated rejection (over Banff II acute&#xD;
             rejection), recurrent acute rejection (&gt;1 episode), or steroid resistant rejection&#xD;
             post-transplant&#xD;
&#xD;
          6. History of antibody-mediated rejection (acute or chronic)&#xD;
&#xD;
          7. History of rejection 2 months prior to inclusion&#xD;
&#xD;
          8. Documented presence of donor specific antibodies (DSA) according to local lab results&#xD;
             at baseline&#xD;
&#xD;
          9. Panel reactive antibody (PRA) &gt;20% prior to transplantation, measured according to&#xD;
             local standard&#xD;
&#xD;
         10. Patients receiving or having received Sirolimus, Everolimus, Azathioprine, Belatacept&#xD;
             or Cyclophosphamide within 3 months prior to enrolment&#xD;
&#xD;
         11. Patients having received any other induction therapy than Basiliximab (e.g. depleting&#xD;
             polyclonal antithymocyte antibodies (ATG), OKT3, Alemtuzumab)&#xD;
&#xD;
         12. Patients with proteinuria &gt;1.0 g/day (or &gt;1.0 g/g creatinine) at screening or having&#xD;
             experienced nephrotic syndrome due to recurrence of focal segmental glomerulosclerosis&#xD;
             (FSGS)&#xD;
&#xD;
         13. History of alcohol or drug abuse with less than 6 months of sobriety&#xD;
&#xD;
         14. Patient with a known hereditary immunodeficiency&#xD;
&#xD;
         15. Patient with active malignancy posttransplant with the exception of local,&#xD;
             non-invasive, fully excised, cutaneous basal cell carcinoma, cutaneous squamous cell&#xD;
             carcinoma, or cervical carcinoma in situ&#xD;
&#xD;
         16. Patients with clinically symptomatic congestive heart failure or symptomatic coronary&#xD;
             artery disease&#xD;
&#xD;
         17. Patients with documented (either by serology and/or nuclear acid testing (NAT)&#xD;
             clinically active infections (e.g. with a known Hepatitis B, Hepatitis C, HIV, CMV or&#xD;
             BK virus infection)&#xD;
&#xD;
         18. Participation in any other investigational clinical trial 3 months before&#xD;
             participation in this study, except the SENIOR transplant registry&#xD;
&#xD;
         19. Patients with leukopenia (&lt;2500 cells/nl) or neutropenia (&lt;1500 cells/nl)&#xD;
&#xD;
         20. Patients with thrombocytopenia (&lt;100 cells/nl)&#xD;
&#xD;
         21. Patients with liver transaminases or bilirubin values &gt; 3x normal values&#xD;
&#xD;
         22. Any significant diseases or clinically significant findings, including psychiatric and&#xD;
             behavioural problems, medical history and/or physical examination findings that would&#xD;
             in the opinion of the investigator preclude the patient from participating in the&#xD;
             study.&#xD;
&#xD;
         23. Patients who have been institutionalized by official or court order&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klemens Budde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite Universitaetsmedizin Berlin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lukas J Lehner, MD</last_name>
    <phone>004930450613559</phone>
    <email>lukas.lehner@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Klemens Budde, MD</last_name>
    <phone>004930450614086</phone>
    <email>klemens.budde@charite.de</email>
  </overall_contact_backup>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>April 3, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Klemens Budde</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>kidney transplantation</keyword>
  <keyword>senior kidney transplant recipients</keyword>
  <keyword>tacrolimus once daily</keyword>
  <keyword>reduced immunosuppression</keyword>
  <keyword>recipients &gt;65 years</keyword>
  <keyword>Senior</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>aggregated data are available through the Steering committee of DESCARTES and EKITA</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

